Analysis of Operator Expertise in MRI/TRUS Fusion-Guided Prostate Biopsy
<b>Background/Objectives</b>: This study analyzed the impact of operator experience on the detection of PC and csPC using a standardized MRI/TRUS-fusion biopsy protocol in an experienced high-volume center. <b>Methods</b>: Men with mpMRI and subsequent combined TB and SB (2019-2024) using transrectal, software-assisted MRI/TRUS-fusion were retrospectively included. Operators were stratified by experience subgroups (<100 vs. ≥100 procedures). Clinical, MRI, and biopsy data have been assessed. The primary objective was the analysis of the effect of biopsy experience on patient-level PC detection. The secondary objective was the PC detection of PI-RADS and DRE. <b>Results</b>: A total of 683 consecutive patients were included (median age 63 years, median PSA 6.5 ng/mL, and median prostate volume 41 mL). Overall, PC and csPC detection were 67% and 51%, with no significant difference in the operator experience subgroups (<i>p</i> = 0.63; <i>p</i> = 0.23). There were no significant differences for additional csPC detection by SB (7% vs. 5%; <i>p</i> = 0.31) or TB (9% vs. 10%; <i>p</i> = 0.93) in both subgroups. DRE showed limited diagnostic value (SEN 32%, SPE 88%, PPV 74%, NPV 55%) with no significant variation regarding the experience (<i>p</i> = 0.12-1.0). Limitations include a single-center, retrospective design and a lack of a radical prostatectomy specimen. <b>Conclusions</b>: In a standardized MRI-targeted biopsy setting, operator experience seems to have a lower influence on PC or csPC detection. High csPC detection in PI-RADS 4-5 supports a TB-only approach, while low rates in PI-RADS 3 suggest follow-up MRI over immediate biopsy. Limited DRE accuracy highlights its declining role in PC assessment.
Authors
- Matthias Boschheidgen (ORCID: https://orcid.org/0000-0002-1522-6374)
- Rouvier Al‐Monajjed (ORCID: https://orcid.org/0009-0009-1004-1459)
- Alexandra Ljimani (ORCID: https://orcid.org/0000-0002-9748-9927)
- Jale Lakes
- J.P. Radtke (ORCID: https://orcid.org/0000-0001-5266-8297)
- Gerald Antoch (ORCID: https://orcid.org/0000-0001-7834-3714)
- Iréne Esposito (ORCID: https://orcid.org/0000-0002-0554-2402)
- Peter Albers (ORCID: https://orcid.org/0000-0002-1747-9615)
- Lars Schimmöller (ORCID: https://orcid.org/0000-0001-7476-292X)
- T. Ullrich (ORCID: https://orcid.org/0000-0002-9866-8898)
- Anne Hübner
- Isabelle Bußhoff (ORCID: https://orcid.org/0009-0002-2173-5770)
- Anna Herzum
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Universitätsklinik Marien Hospital Herne (DE)
- Düsseldorf University Hospital (DE)
- Integrated Oncology (United States) (US)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- Cancers
- Published
- 2025-11-28
- DOI
- https://doi.org/10.3390/cancers17233811
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00